Main Article Content

Rola Husni
Remie Chrabieh
Rita Wilson Dib
Jose Vazquez, MD
Thaís Guimarães
Ana Fernández
Rita Khoury
Lina Asmar
Georges Khazen
Nadia Lara Samaha
Issam Raad
Ray Hachem


Candida infection, Neutropenia, Bloodstream Infections


Background: Candida bloodstream infection (BSI) remains one of the leading causes of BSI in critically ill and immunosuppressed cancer patients. In light of the changing epidemiology and rising resistant species, duration of treatment and appropriate timing of stepdown therapy from intravenous (IV) to oral antifungal agents are crucial for utmost disease control and overall survival.

Method: We performed a multicenter retrospective study, with 119 non-neutropenic patients enrolled from four different medical institutions in Brazil, Lebanon ,Spain and the United States, to assess the duration of IV therapy and appropriate time to step down to oral therapy in adult patients, 14 years of age and older, with documented candidemia. The analysis was done using the statistical program R and SAS v9.4. Descriptive statistics are presented as frequencies and tables and the Fisher exact test was used to test the association between the categorical variables: organism, cancer, country, antifungal drug and duration of therapy, and time of step-down.

Results: Candida albicans contributed to 45% bloodstream infection versus 55% infection caused Candida non-albicans. The three most common Candida non-albicans are: Candida glabrata 24%, Candida parapsilosis 13% and Candida tropicalis 8%. Most (57%) of the patients were admitted to ICU whereas 52% had underlying malignancy. Multivariate analysis showed that a stay at ICU or an underlying cancer requiring chemotherapy were independently associated with failure and death (p <0.001). The average total duration of therapy was 14 days in all patients and 16 days in those who responded and survived. There were 45 patients who were stepped down to either fluconazole and/or voriconazole in association with clinical and microbiologic resolution of the candidemia. The average (and median) day of step down was 5 days. Patients who had a stepdown had more successful outcomes (78% survival) as compared to those with no stepdown (56% survival) (P = 0.022). However, the 20 patients who received 1-4 days of first IV treatment before a stepdown to oral azoles had a comparable outcome (20% mortality) to the 25 patients who received >5 days of treatment (24% mortality - p = 0.75).


Our data support the IDSA guidelines in that the total duration of treatment for candidemia should be at least 14 days after a negative blood culture. However, in non-neutropenic cancer patients with candidemia, a step down to oral azole therapy can safely take place early (within 4 days of initiating IV therapy) as long as the patient had clinical and microbiologic resolution of the bloodstream infections.


Download data is not yet available.

Abstract 1015
PDF Downloads 383
HTML Downloads 130


1. Vincent, J.L., J. Rello, J. Marshall, E. Silva, et al., International study of the prevalence and outcomes of infection in intensive care units. JAMA, 2009. 302(21): 2323-9.
2. Martin, G.S., D.M. Mannino, S. Eaton, and M. Moss, The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med, 2003. 348(16): 1546-54.
3. Gudlaugsson, O., S. Gillespie, K. Lee, J. Vande Berg, et al., Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis, 2003. 37(9): 1172-7.
4. Pappas, P.G., J.H. Rex, J. Lee, R.J. Hamill, et al., A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis, 2003. 37(5): 634-43.
5. Pappas, P.G., C.A. Kauffman, D.R. Andes, C.J. Clancy, et al., Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis, 2016. 62(4): e1-50.
6. Kuse, E.R., P. Chetchotisakd, C.A. da Cunha, M. Ruhnke, et al., Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet, 2007. 369(9572): 1519-1527.
7. Rex, J.H., J.E. Bennett, A.M. Sugar, P.G. Pappas, et al., A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med, 1994. 331(20): 1325-30.
8. Pappas, P.G., C.M. Rotstein, R.F. Betts, M. Nucci, et al., Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis, 2007. 45(7): 883-93.
9. Betts, R.F., M. Nucci, D. Talwar, M. Gareca, et al., A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis, 2009. 48(12): 1676-84.
10. Morrell, M., V.J. Fraser, and M.H. Kollef, Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother, 2005. 49(9): 3640-5.
11. Cornely, O.A., M. Bassetti, T. Calandra, J. Garbino, et al., ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect, 2012. 18 Suppl 7: 19-37.
12. Vazquez, J., A.C. Reboli, P.G. Pappas, T.F. Patterson, et al., Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial. BMC Infect Dis, 2014. 14: 97.
13. Kullberg, B.J., J.D. Sobel, M. Ruhnke, P.G. Pappas, et al., Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet, 2005. 366(9495): 1435-42.
14. Wisplinghoff, H., T. Bischoff, S.M. Tallent, H. Seifert, et al., Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis, 2004. 39(3): 309-17.
15. Marchetti, O., J. Bille, U. Fluckiger, P. Eggimann, et al., Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis, 2004. 38(3): 311-20.
16. Pfaller, M.A. and D.J. Diekema, Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev, 2007. 20(1): 133-63.
17. Horn, D.L., D. Neofytos, E.J. Anaissie, J.A. Fishman, et al., Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis, 2009. 48(12): 1695-703.
18. Sipsas, N.V. and D.P. Kontoyiannis, Invasive fungal infections in patients with cancer in the Intensive Care Unit. Int J Antimicrob Agents, 2012. 39(6): 464-71.
19. Slavin, M.A., T.C. Sorrell, D. Marriott, K.A. Thursky, et al., Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death. J Antimicrob Chemother, 2010. 65(5): 1042-51.
20. Sipsas, N.V., R.E. Lewis, J. Tarrand, R. Hachem, et al., Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer, 2009. 115(20): 4745-52.
21. Leroy, O., J.P. Mira, P. Montravers, J.P. Gangneux, et al., Comparison of albicans vs. non-albicans candidemia in French intensive care units. Crit Care, 2010. 14(3): R98.
22. Sun, M., C. Chen, W. Xiao, Y. Chang, et al., Increase in Candida Parapsilosis Candidemia in Cancer Patients. Mediterr J Hematol Infect Dis, 2019. 11(1): e2019012.
23. Guinea, J., Global trends in the distribution of Candida species causing candidemia. Clin Microbiol Infect, 2014. 20 Suppl 6: 5-10.
24. Richardson, M. and C. Lass-Florl, Changing epidemiology of systemic fungal infections. Clin Microbiol Infect, 2008. 14 Suppl 4: 5-24.
25. Cuenca-Estrella, M., D. Rodriguez, B. Almirante, J. Morgan, et al., In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. J Antimicrob Chemother, 2005. 55(2): 194-9.
26. Pfaller, M.A., S.A. Messer, G.J. Moet, R.N. Jones, et al., Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009). Int J Antimicrob Agents, 2011. 38(1): 65-9.
27. Bassetti, M., M. Merelli, E. Righi, A. Diaz-Martin, et al., Epidemiology, species distribution, antifungal susceptibility, and outcome of candidemia across five sites in Italy and Spain. J Clin Microbiol, 2013. 51(12): 4167-72.
28. Cisterna, R., G. Ezpeleta, O. Telleria, and G. Spanish Candidemia Surveillance, Nationwide sentinel surveillance of bloodstream Candida infections in 40 tertiary care hospitals in Spain. J Clin Microbiol, 2010. 48(11): 4200-6.
29. Nucci, M., F. Queiroz-Telles, A.M. Tobon, A. Restrepo, et al., Epidemiology of opportunistic fungal infections in Latin America. Clin Infect Dis, 2010. 51(5): 561-70.
30. Lamoth, F., S.R. Lockhart, E.L. Berkow, and T. Calandra, Changes in the epidemiological landscape of invasive candidiasis. J Antimicrob Chemother, 2018. 73(suppl_1): i4-i13.
31. Garey, K.W., M. Rege, M.P. Pai, D.E. Mingo, et al., Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis, 2006. 43(1): 25-31.
32. Kaur, H. and A. Chakrabarti, Strategies to Reduce Mortality in Adult and Neonatal Candidemia in Developing Countries. J Fungi (Basel), 2017. 3(3).
33. Andes, D.R., N. Safdar, J.W. Baddley, G. Playford, et al., Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis, 2012. 54(8): 1110-22.
34. Hirano, R., Y. Sakamoto, K. Kudo, and M. Ohnishi, Retrospective analysis of mortality and Candida isolates of 75 patients with candidemia: a single hospital experience. Infect Drug Resist, 2015. 8: 199-205.
35. Labelle, A.J., S.T. Micek, N. Roubinian, and M.H. Kollef, Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med, 2008. 36(11): 2967-72.
36. Kollef, M., S. Micek, N. Hampton, J.A. Doherty, et al., Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis, 2012. 54(12): 1739-46.
37. Dib, R.W., R. Hachem, A.M. Chaftari, and I. Raad, Appropriate Duration of Intravenous Treatment of Candidemia and Timing of Step Down to Oral Therapy in Non-neutropenic Patients. Mediterr J Hematol Infect Dis, 2018. 10(1): e2018028.

Similar Articles

<< < 1 2 3 > >> 

You may also start an advanced similarity search for this article.